US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2024
0mins
Should l Buy ?
Source: Reuters
Supreme Court Decision: The U.S. Supreme Court declined to hear Norwich Pharmaceuticals' appeal against a lower court ruling that blocked its attempt to sell a generic version of Bausch Health's Xifaxan, citing patent infringement concerns related to treating hepatic encephalopathy.
Financial Impact: Bausch Health earned over $1.8 billion from Xifaxan sales in 2023, while Norwich argued that the delay in introducing generic alternatives would lead to higher costs for patients and the healthcare system.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
